Description
An Aurora kinase inhibitor; inhibits Aurora A and B by 82 and 60%, respectively, at 1 μM in cell free assays; selective for Aurora A and B over a panel of 13 kinases at 1 μM; inhibits growth of various cancer cell lines (GI50s = 0.08-1.2 μM); induces DNA accumulation and cell cycle arrest at the G2/M phase, as well as apoptosis in HCT116 cells; increases the accumulation of doxorubicin and rhodamine 123 in MDR KBv200 and MCF-7/adr cells and increases the susceptibility of MDR KBv200, MCF-7/adr, S1-M1-80, and HL60/adr cells to cisplatin and doxorubicin; reduces tumor growth in an HCT116 mouse xenograft model at 100 mg/kg; potentiates the antitumor effects of vincristine in a KBv200 mouse xenograft model
Formal name: 4-[6-chloro-2-[4-(dimethylamino)phenyl]-3H-imidazo[4,5-b]pyridin-7-yl]-N-2-thiazolyl-1-piperazineacetamide
Synonyms:
Molecular weight: 497
CAS: 942947-93-5
Purity: ≥98%
Formulation: A crystalline solid